SCHEMBL16455285

SCHEMBL16455285

CS(=O)(=O)c1cccc(-c2nc(-c3cc(C(=O)O)nn3-c3ccccc3C(F)(F)F)no2)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 10/20 0.55
NR1H3 Q13133 9/20 0.55
RXRA P19793 6/20 0.55
S1PR1 P21453 3/20 0.44
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
HTT P42858 1/20 0.42
HSD11B1 P28845 1/20 0.41
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA9 Q16790 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
CPT2 P23786 1/20 0.39
CPT1A P50416 1/20 0.39
S1PR3 Q99500 1/20 0.38
CARM1 Q86X55 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16587436 0.91 RXRA (0.57) NR1H2NR1H3RXRAS1PR1ALDH1A1
SCHEMBL16455591 0.87 RXRA (0.57) NR1H2NR1H3RXRAS1PR1ALDH1A1
SCHEMBL16455253 0.86 NR1H2 (0.54) NR1H2NR1H3RXRAALDH1A1MAPT
SCHEMBL3471844 0.84 NR1H2 (0.78) NR1H2NR1H3RXRAALDH1A1MAPT
SCHEMBL19633207 0.83 NR1H3 (0.54) NR1H2NR1H3RXRAS1PR1HSD11B1
SCHEMBL16455659 0.83 NR1H2 (0.49) NR1H2NR1H3RXRAS1PR1HSD11B1
SCHEMBL16455512 0.82 NR1H2 (0.51) NR1H2NR1H3RXRAS1PR1HSD11B1
SCHEMBL15242940 0.82 NR1H2 (0.54) NR1H2NR1H3RXRAALDH1A1MAPT
SCHEMBL16455247 0.81 NR1H2 (0.60) NR1H2NR1H3RXRAALDH1A1MAPT
SCHEMBL16455513 0.80 NR1H2 (0.49) NR1H2NR1H3RXRAS1PR1HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210101895-A1 LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS RALEXAR THERAPEUTICS, INC. 2021-04-08 US disclosed
EP-3441390-A1 LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS Ralexar Therapeutics, Inc. (US) 2019-02-13 EP disclosed
US-20170334897-A1 Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions ALEXAR THERAPEUTICS, INC. 2017-11-23 US disclosed
US-9637481-B2 Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions RALEXAR THERAPEUTICS, INC. (US) 2017-05-02 US disclosed
US-20150152094-A1 LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS RALEXAR THERAPEUTICS, INC. 2015-06-04 US disclosed
US-8987318-B2 Liver X receptor (LXR) modulators for the treatment of dermal diseases, disorders and conditions ALEXAR THERAPEUTICS, INC. (US) 2015-03-24 US disclosed
US-20150045399-A1 Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions ALEXAR THERAPEUTICS, INC. (US) 2015-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045399-A1 Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions NR1H2, NR1H3, RXRA NR1H2 1/4885NR1H3 2/4885RXRA 3/4885
US-20170334897-A1 Liver X Receptor (LXR) Modulators For The Treatment Of Dermal Diseases, Disorders And Conditions NR1H2, NR1H3, RXRA NR1H2 1/4885NR1H3 2/4885RXRA 3/4885
US-20210101895-A1 LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS NR1H2, NR1H3, RXRG NR1H2 1/4885NR1H3 2/4885RXRA 4/4885
US-20150152094-A1 LIVER X RECEPTOR (LXR) MODULATORS FOR THE TREATMENT OF DERMAL DISEASES, DISORDERS AND CONDITIONS NR1H2, NR1H3, RXRA NR1H2 1/4885NR1H3 2/4885RXRA 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.